About Us

---

To bridge the gap between breakthrough discovery and patient impact. We bring deep expertise in oncology, gene therapy, and translational research to move promising therapies from preclinical proof to clinical reality.

After years of leading early-phase oncology and gene therapy programs, our team saw the same barrier: innovative ideas often stalled before reaching the clinic not because science failed, but because strategy was missing. CellGene Nexus was founded to change that narrative with senior, hands-on guidance from lab to IND.

• 15+ years in oncology, translational, and regulatory science.
• Preclinical strategy & experimental design (cells & humanized mouse models) aligned to FDA IND standards.
• IND-enabling program development across tox, biodistribution, and efficacy studies (GLP-aware).
• 90+ peer-reviewed publications and global presentations in precision medicine.
• Deep roots in the Houston / Texas Medical Center innovation ecosystem.